225 results
Page 4 of 12
8-K
EX-99.1
dryydxw0nx2r3rdsiv
5 Nov 20
Achieved Sequential Revenue Growth of 28% in Third Quarter of 2020, Driven by Detection
4:01pm
8-K
EX-99.1
d5gsg5d9
4 Aug 20
Launched ProFound AI™ Risk Offering After Receiving CE Mark in Europe
4:10pm
8-K
EX-10.3
rsypl0rg0
29 May 20
Departure of Directors or Certain Officers
4:05pm
8-K
EX-10.1
98rvmp 9xb
29 May 20
Departure of Directors or Certain Officers
4:05pm
8-K
EX-10.4
mmjdztnyoq
29 May 20
Departure of Directors or Certain Officers
4:05pm
8-K
EX-10.2
zw8nut
29 May 20
Departure of Directors or Certain Officers
4:05pm
8-K
EX-99.1
7d6vvf8earp
11 May 20
Recent Equity Offering Strengthens Balance Sheet and Increases Operating Flexibility with focus on Brain Cancer Initiatives
4:24pm
8-K
EX-10.1
0gic9nuv35znt6t8zuo0
27 Apr 20
Entry into a Material Definitive Agreement
5:21pm
8-K
EX-99.1
zyecc16dkf vcm7
27 Apr 20
Entry into a Material Definitive Agreement
5:21pm
424B5
91bpl4rrdkveqao vw
24 Apr 20
Prospectus supplement for primary offering
5:11pm
8-K
EX-10.2
woq1f3e
31 Mar 20
Entry into a Material Definitive Agreement
9:03am
424B5
qe90l7qt5yqi7yfqqykz
31 Mar 20
Prospectus supplement for primary offering
9:01am
8-K
EX-99.1
4h6 jj5xw
28 Feb 20
Strong Q4 2019 revenue growth of 35% driven by a 39% increase in revenue from iCAD’s AI Cancer Detection segment
8:32am
8-K
qftudi tp0gj0
17 Jan 20
Departure of Directors or Certain Officers
4:58pm
8-K
EX-10.1
2sk1ra isy0zafuc
17 Jan 20
Departure of Directors or Certain Officers
4:58pm